Lexicon Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US5288721047
Biotechnology & Medical Research
| Market Cap | 1.02B 877M 820M 751M 1.41B 97.92B 1.43B 9.69B 3.78B 49.19B 3.84B 3.76B 163B | P/E 2026 * |
-13.7x | P/E 2027 * | -12.3x |
|---|---|---|---|---|---|
| Enterprise Value | 1.02B 877M 820M 751M 1.41B 97.92B 1.43B 9.69B 3.78B 49.19B 3.84B 3.76B 163B | EV / Sales 2026 * |
27x | EV / Sales 2027 * | 51.4x |
| Free-Float |
98.45% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Lexicon Pharmaceuticals, Inc.
| 1 day | +7.56% |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Exton
CEO | Chief Executive Officer | 56 | 2024-07-07 |
Scott Coiante
DFI | Director of Finance/CFO | 59 | 2025-01-01 |
Michael Davies
CTO | Chief Tech/Sci/R&D Officer | - | 2025-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Samuel Barker
CHM | Chairman | 83 | 2004-12-31 |
Ray Debbane
CHM | Chairman | 71 | 2012-02-26 |
| Director/Board Member | 67 | 2007-08-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.56% | +0.99% | - | - | 970M | |
| -3.00% | +2.27% | +77.60% | +109.33% | 73.96B | |
| +1.90% | +23.53% | +56.60% | +97.76% | 64.66B | |
| +5.12% | +25.22% | +5.24% | -0.82% | 27.86B | |
| +0.55% | +1.64% | -5.15% | +471.68% | 27.32B | |
| +2.74% | +12.98% | +62.84% | +28.14% | 25.97B | |
| +0.47% | +6.12% | +36.66% | -13.79% | 19.98B | |
| +1.82% | -6.67% | +247.46% | +393.10% | 17.84B | |
| +0.94% | +3.36% | +18.55% | +532.94% | 16.24B | |
| +0.73% | +5.54% | +39.71% | +153.07% | 13.3B | |
| Average | +1.88% | +7.62% | +59.94% | +196.82% | 31.9B | |
| Weighted average by Cap. | +0.71% | +8.75% | +59.25% | +158.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.95M 32.51M 30.41M 27.84M 52.25M 3.63B 52.94M 359M 140M 1.82B 142M 139M 6.03B | 19.91M 17.06M 15.96M 14.61M 27.42M 1.91B 27.78M 189M 73.54M 957M 74.77M 73.15M 3.17B |
| Net income | -72.44M -62.05M -58.06M -53.15M -99.74M -6.93B -101M -686M -267M -3.48B -272M -266M -11.52B | -90.96M -77.92M -72.91M -66.74M -125M -8.7B -127M -861M -336M -4.37B -342M -334M -14.46B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
